- Conditions
- Bronchopulmonary Dysplasia, Encephalomalacia, Premature Birth
- Interventions
- Hydrocortisone, Placebo
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Week to 3 Weeks
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 10,335
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Birth Defects, Pregnancy Complications, Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Syneos Health
- Other
- Eligibility
- Female only
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Gaucher's Disease Type III
- Interventions
- Venglustat, imiglucerase
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Iowa City, Iowa • Dallas, Texas + 1 more
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
- Interventions
- CB-839, Capecitabine
- Drug
- Lead sponsor
- David Bajor, MD
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Hereditary Angioedema, HAE
- Interventions
- BCX7353 capsules, Placebo oral capsule
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- Skin Laxity
- Interventions
- Ulthera System Treatment
- Device
- Lead sponsor
- Ulthera, Inc
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Mesa, Arizona
- Conditions
- Skin Diseases
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Down Syndrome, Alzheimer's Dementia
- Interventions
- biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy
- Procedure · Other
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,083 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Peoria, Arizona • Tempe, Arizona + 33 more
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Milene Saavedra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Nitrous oxide 50%
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
- Interventions
- AR882 50 mg, AR882 75 mg, Placebo
- Drug
- Lead sponsor
- Arthrosi Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 818 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Foley, Alabama • Anchorage, Alaska • Peoria, Arizona + 47 more
- Conditions
- Congenital Heart Disease (CHD)
- Interventions
- 2 mL SunButyrate-TG, Placebo, 4 mL SunButyrate-TG
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 1 Month to 3 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Tetrology of Fallot, Heart Ventricle, Hypoplastic Left Heart
- Interventions
- Dexmedetomidine
- Drug
- Lead sponsor
- Athena Zuppa
- Other
- Eligibility
- 1 Hour to 30 Days
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Congenital Heart Disease, Single-ventricle
- Interventions
- Transthoracic Echocardiogram or Cardiac MRI, Ventripoint Echocardiogram
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Netherton Syndrome
- Interventions
- BCX17725, Placebo
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
- Conditions
- Fabry Disease
- Interventions
- pegunigalsidase alfa
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more
- Conditions
- Fetal Growth Retardation
- Interventions
- Fetal Genome Profiling.
- Diagnostic Test
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain Diseases, Metabolic, Inborn, Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency
- Interventions
- Not listed
- Lead sponsor
- Andrea Gropman
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia
- Interventions
- Niacin Extended Release/Lovastatin
- Drug
- Lead sponsor
- In His Image
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Fremont, California + 30 more
- Conditions
- Hereditary Cancer Syndrome
- Interventions
- Mainstream Genetic Testing Model, Enhanced Standard of Care Model
- Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Jaundice, Neonatal, Hyperbilirubinemia, Bilirubin-Induced Neurological Dysfunction (BIND)
- Interventions
- Bilirubin Binding Capacity by Hematofluorometry Validation
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Hours to 14 Days
- Enrollment
- 161 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Stanford, California • Lakewood, New Jersey
- Conditions
- Friedreich's Ataxia
- Interventions
- alpha-tocopherolquinone (A0001), placebo
- Drug
- Lead sponsor
- Penwest Pharmaceuticals Co.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania